3-{5-(4-bromophenyl)-1-[3-(trifluoromethyl)phenyl]-1H-pyrrol-2-yl}propanoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 3-{5-(4-bromophenyl)-1-[3-(trifluoromethyl)phenyl]-1H-pyrrol-2-yl}propanoic acid
• 英文别名: 3-[5-(4-bromophenyl)-1-[3-(trifluoromethyl)phenyl]pyrrol-2-yl]propanoic acid
• 化学式: C₂₀H₁₅BrF₃NO₂
• mdl: MFCD03706343
• 分子量: 438.2
• InChiKey: LVUDWSVFXDNMHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Ghrelin receptor inverse agonists for regulation of feeding behaviors
  申请人：Lange H. Birgitte

  公开号：US20060025344A1

  公开（公告）日：2006-02-02

  Compounds of the invention act as inverse agonist ghrelin receptors. Some of the compounds of the invention may have both inverse agonistic and antagonistic properties as they both decrease or eliminate the constitutive activity of he ghrelin receptor and block the effect of ghrelin. Other preferred compounds of the invention have inverse agonistic properties but have little or no antagonistic activity. The compounds are suitable for medical and/or cosmetic use in connection with modulation of feeding behaviors, body composition and reduction of body mass. The invention also relates to methods for identifying inverse agonists for the ghrelin receptor and for monitoring the further development of such compounds.

  本发明的化合物可作为胃泌素受体的反向激动剂。本发明的某些化合物可能同时具有反向激动和拮抗特性，因为它们既能降低或消除胃泌素受体的组成活性，又能阻断胃泌素的作用。本发明的其他优选化合物具有反向激动特性，但几乎没有或根本没有拮抗活性。这些化合物适用于调节进食行为、身体组成和减少体重的医疗和/或美容用途。本发明还涉及鉴定胃泌素受体反向激动剂和监测此类化合物进一步开发的方法。
• GHRELIN RECEPTOR INVERSE AGONIST FOR REGULATION OF FEEDING BEHAVIOURS
  申请人：7TM Pharma A/S

  公开号：EP1578798A1

  公开（公告）日：2005-09-28
• [EN] GHRELIN RECEPTOR INVERSE AGONIST FOR REGULATION OF FEEDING BEHAVIOURS<br/>[FR] AGONISTE INVERSE DU RECEPTEUR DE LA GHRELINE POUR REGULER DES COMPORTEMENTS ALIMENTAIRES
  申请人：7TM PHARMA AS

  公开号：WO2004056869A1

  公开（公告）日：2004-07-08

  Compounds of the invention act as inverse agonist ghrelin receptors. Some of the compounds of the invention may have both inverse agonistic and antagonistic properties as they both decrease or eliminate the constitutive activity of he ghrelin receptor and block the effect of ghrelin. Other preferred compounds of the invention have inverse agonistic properties but have little or no antagonistic activity. The compounds are suitable for medical and/or cosmetic use in connection with modulation of feeding behaviors, body composition and reduction of body mass. The invention also relates to methods for identifying inverse agonists for the ghrelin receptor and for monitoring the further development of such compounds.